<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588884</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP101-CL-4001</org_study_id>
    <nct_id>NCT03588884</nct_id>
  </id_info>
  <brief_title>Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI</brief_title>
  <official_title>An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of
      Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and
      Paricalcitol Plus Low-Dose Cholecalciferol in Patients with Secondary Hyperparathyroidism,
      Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2018</start_date>
  <completion_date type="Anticipated">May 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events as assessed by CTCAE version 5.0</measure>
    <time_frame>5 months</time_frame>
    <description>Detailed information collected for each TEAE will include: AE number, a description of the event, start date, end date or ongoing as of date, outcome, therapy for event</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Secondary Hyperparathyroidism Due to Renal Causes</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>CKD Stage 3</condition>
  <condition>CKD Stage 4</condition>
  <arm_group>
    <arm_group_label>CTAP101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTAP101/Calcifediol Capsules 60 mcg once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate-release (IR) calcifediol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate-release (IR) calcifediol/266 mcg capsule before breakfast on the mornings of Day 1 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol/Capsules 300,000 IU (high-dose) before breakfast on the mornings of Day 1 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and 29 when dosing will occur before breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol Oral Capsule</intervention_name>
    <description>Capsule, daily</description>
    <arm_group_label>CTAP101</arm_group_label>
    <other_name>CTAP101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol Oral Product</intervention_name>
    <description>Capsule, once a month</description>
    <arm_group_label>Immediate-release (IR) calcifediol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Capsule, once a month</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_label>Paricalcitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol Oral Capsule</intervention_name>
    <description>Capsule, daily</description>
    <arm_group_label>Paricalcitol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be at least 18 years of age.

          2. Have stage 3 or 4 CKD (eGFR of ≥15 to &lt;60 mL/min/1.73m2 using the Modification of Diet
             in Renal Disease equation).

          3. Be without any disease state or physical condition that might impair evaluation of
             safety and efficacy or which, in the Investigator's opinion, would interfere with
             study participation, including:

               1. Serum albumin ≤ 3.0 g/dL;

               2. Serum transaminase (alanine transaminase, glutamic pyruvic transaminase,
                  aspartate aminotransferase or glutamic oxaloacetic transaminase) &gt; 2.5 times the
                  upper limit of normal at screening; and,

               3. Urinary albumin excretion ≤3000 μg/mg creatinine.

          4. Exhibit during the initial screening visit:

               1. Plasma iPTH ≥70 pg/mL and &lt;400 pg/mL if receiving calcitriol or other 1α-
                  hydroxylated vitamin D analog (paricalcitol or doxercalciferol); or

               2. Plasma iPTH ≥100 pg/mL and &lt;500 pg/mL if not receiving calcitriol or other 1α-
                  hydroxylated vitamin D analog; and,

               3. Serum total 25-hydroxyvitamin D &lt;30 ng/mL.

          5. If taking calcitriol, other 1α-hydroxylated vitamin D analog, or vitamin D
             supplementation, must forgo treatment with these non-study agents for the duration of
             the study and undergo a 4-week washout period.

          6. Exhibit after the 4-week washout period (if required):

               1. Plasma iPTH ≥100 pg/mL and &lt;500 pg/mL;

               2. Corrected serum calcium &lt;9.8 mg/dL; (corrected for serum albumin)

               3. Serum total 25-hydroxyvitamin D &lt;30 ng/mL; and,

               4. Serum phosphorus &lt;5.5 mg/dL.

          7. If taking more than 1,500 mg/day of elemental calcium, reduce calcium use (to
             approximately 1,000 to ≤1,500 mg/day) for the duration of the study.

          8. Willing and able to comply with study instructions and commit to all clinic visits for
             the duration of the study.

          9. Female subjects of childbearing potential must be neither pregnant nor lactating and
             must have negative blood pregnancy tests at the first screening visit.

         10. All female subjects of childbearing potential and male subjects with female partners
             of childbearing potential must agree to use effective contraception (implants,
             injectables, combined oral contraceptives, intrauterine device, sexual abstinence,
             vasectomy or vasectomized partner) for the duration of the study.

         11. Be able to read, understand and sign the subject Informed Consent Form (ICF) or have a
             legal authorized representative (LAR) sign the ICF.

        Exclusion Criteria:

          1. History of or planned kidney transplant or parathyroidectomy

          2. History (prior 3 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus
             ≥5.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.

          3. Need for phosphate binders to maintain the serum phosphate &lt; 5.5 mg/dL or use of
             phosphate binders within 4 weeks prior to screening

          4. Use of calcimimetic therapy (cinacalcet or etelcalcetide) within 12 weeks of
             screening.

          5. Receipt of bisphosphonate therapy or other bone modifying treatment within 6 months
             prior to enrollment.

          6. Known previous or concomitant serious illness or medical condition, such as
             malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic
             disease, intestinal malabsorption disorder, hepatitis or cardiovascular event that in
             the opinion of the Investigator may worsen or reduce life expectancy, and/or interfere
             with participation in the study.

          7. History of neurological/psychiatric disorder, including psychotic disorder or
             dementia, or any reason which, in the opinion of the Investigator makes adherence to a
             treatment or follow-up schedule unlikely.

          8. Known or suspected hypersensitivity to any of the constituents of the study drugs.

          9. Currently participating in, or has participated in, an interventional/investigational
             study within 30 days prior to study screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luis Paredes</last_name>
    <phone>305-575-4167</phone>
    <email>lparedes@opko.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evelyn Cheng</last_name>
    <phone>305-575-4129</phone>
    <email>echeng@opko.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute of Clinical Research, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Dudley</last_name>
      <phone>323-206-5544</phone>
      <email>rdudley@nicresearch.com</email>
    </contact>
    <investigator>
      <last_name>AJIT S. SAWHNEY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Ross</last_name>
      <phone>708-952-3040</phone>
      <email>bross@researchbd.com</email>
    </contact>
    <investigator>
      <last_name>Paul Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randy Spaulding</last_name>
      <phone>262-206-3085</phone>
      <email>Randy.Spaulding@spauldingclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Angie Bartkus</last_name>
      <phone>262-334-6020</phone>
      <email>angela.bartkus@spauldingclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Sanabria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

